Meditex Pharma Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
as on 21-06-2024
- Paid Up Capital ₹ 2.50 M
as on 21-06-2024
- Company Age 62 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Revenue -0.56%
(FY 2016)
- Profit -9.77%
(FY 2016)
- Ebitda -74.36%
(FY 2016)
- Net Worth 10.10%
(FY 2016)
- Total Assets 10.80%
(FY 2016)
About Meditex Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 2.50 M, as per Ministry of Corporate Affairs (MCA) records.
Kasi Krishnan, Kasi Sundaram, Jaya Sundaram, and Two other members serve as directors at the Company.
- CIN/LLPIN
U24239HR1962PTC002419
- Company No.
002419
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
23 Jan 1962
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- LocationGurgaon Haryana, Haryana
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Meditex Pharma?
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kasi Sundaram  | Director | 13-May-1967 | Current |
| Kasi Krishnan | Director | 01-Dec-1979 | Current |
| Jaya Sundaram | Director | 01-Sep-1997 | Current |
| Suresh Sundram | Director | 01-Sep-1997 | Current |
| Sunil Sundaram | Director | 25-Mar-2017 | Current |
Financial Performance and Corporate Structure Insights of Meditex Pharma.
Meditex Pharma Pvt Ltd, for the financial year ended 2016, experienced Minor drop in revenue, with a 0.56% decrease. The company also saw a slight decrease in profitability, with a 9.77% decrease in profit. The company's net worth Soared by an impressive increase of 10.1%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Meditex Pharma?
In 2017, Meditex Pharma had a promoter holding of 93.82% and a public holding of 6.18%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Torrins Anthem Private Limited
Active 19 years 5 monthsKasi Sundaram and Sunil Sundaram are mutual person
Eazy Softech Private Limited
Active 24 years 5 monthsKasi Sundaram, Jaya Sundaram and 2 more are mutual person
Spring Hill Technologies Private Limited
Active 17 years 5 monthsKasi Sundaram, Jaya Sundaram and 2 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Meditex Pharma?
Unlock and access historical data on people associated with Meditex Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Meditex Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Meditex Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
